
    
      In this Phase 2 single site RCT, individuals with moderate to severe alcohol use disorder
      (AUD) and presenc eof alcohol withdrawal symptoms (greater than 3 symptoms or more) will be
      enrolled in a 12 week trial with a 1- and 3- month follow up assessment. Subjects will be
      randomized to 16 mh /day Prazosin (PR) or Placebo (PBO) with a 2 week titration period and
      week 12 taper. All subjects will be assessed 2X weekly and also provided weekly behavioral
      counseling to support recovery.
    
  